Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine, Inc. reported that director Ellinor Patrick Thomas II received a grant of stock options covering 103400 shares of common stock. The options have an exercise price of $2.9000 per share, expire on 2036-08-05, and vest in three equal annual installments from 2027-08-06 through 2029-08-06. Following the grant, the director holds 103400 derivative securities directly.
Editas Medicine, Inc. reports that Ellinor Patrick Thomas II is a director and reporting insider on an initial beneficial ownership report. The disclosure shows no reported holdings of common stock or derivative securities and no purchase, sale, option exercise, gift, or other insider transaction activity associated with this person.
Editas Medicine, Inc. executive Amy Parison, SVP and Chief Financial Officer, reported the sale of 678 shares of common stock on August 3, 2026 at $2.58 per share. The sale was executed under a Rule 10b5-1 durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on August 1, 2026 and was not a discretionary trade. Following this transaction, she directly holds 14,292 shares of Editas Medicine common stock.
Editas Medicine reported second-quarter 2026 collaboration and other research and development revenues of $11.9 million, up from $3.6 million a year earlier, and a net loss of $18.2 million versus $53.2 million. Operating expenses fell sharply, helped by the absence of large prior-year restructuring and impairment charges and by a small restructuring benefit in 2026.
As of June 30 2026, cash, cash equivalents and marketable securities totaled $211.6 million, with net cash used in operating activities of $52.6 million in the first half. A May 2026 underwritten offering of 55.6 million shares and accompanying warrants generated $116.9 million in net proceeds, and a liability for the sale of future revenues stood at $55.7 million. Management expects existing cash and cash equivalents to fund operating expenses and capital needs for at least the next twelve months from August 5 2026.
The company is now centered on its in vivo CRISPR candidate EDIT-401 for heterozygous familial hypercholesterolemia, following discontinuation of the reni‑cel program and a workforce reduction of about 65%. Preclinical data showed around 90% or greater LDL‑C reductions in non‑human primates, and a Phase 1/2 trial in Australia and New Zealand is planned, with initial patient data expected in 2027. Editas also continues to recognize collaboration and license revenues from Bristol‑Myers Squibb and Vertex under existing agreements.
Editas Medicine, Inc. reported second quarter 2026 results, with collaboration and other research and development revenue of $11.9 million and a net loss of $18.2 million, or $0.15 per share, compared with a $53.2 million loss a year earlier. Cash and cash equivalents were $211.6 million as of June 30, 2026, and the company expects its cash runway to extend into the second half of 2028.
The company highlighted EDIT-401, its in vivo CRISPR program for Heterozygous Familial Hypercholesterolemia, stating it is on track to submit a Clinical Trial Notification in Australia this month and to initiate a Phase 1/2 trial, with a data update expected in the first quarter of 2027 and topline results in 2027. Preclinical non-human primate data showed roughly 90% or greater mean reductions in LDL-C, Lp(a), and ApoB after a single dose, with no adverse clinical observations at 1.5 mg/kg.
In May, Editas completed a public offering of common stock and warrants for aggregate gross proceeds of $125.0 million, with approximately $194.4 million in additional gross proceeds possible upon full warrant exercise. The company also announced that director Elliott Levy resigned and that Patrick Ellinor, M.D., Ph.D. was appointed as an independent class I director, with standard cash and equity compensation.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly sold 4,928 shares of common stock at $2.67 per share on July 28, 2026. The sale was executed under a durable Rule 10b5-1 automatic sales plan to cover tax withholding from restricted stock units vesting on July 24, 2026 and was not a discretionary trade. Following this transaction, Burkly directly held 62,369 shares of Editas Medicine common stock.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Editas Medicine, Inc.. BlackRock reported beneficial ownership of 8,355,588 shares, representing 4.97% of Editas Medicine’s outstanding common stock.
BlackRock reported sole voting power over 8,226,483 shares and sole dispositive power over 8,355,588 shares, with no shared voting or dispositive power. Various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of Editas Medicine’s outstanding common shares.
Linda C. Burkly has notified of an intention to sell up to 5,500 shares of Common Stock of Editas Medicine on or after 07/27/2026 on NASDAQ. The planned sale relates to shares associated with Restricted Stock Unit vesting, with 11,292 shares shown as acquired from the issuer as equity compensation on 07/24/2026.
During the prior three months, Burkly sold 731 shares of Common Stock for $1,974.50 on 06/03/2026. These details outline upcoming and recent insider share transactions but do not themselves state any change in company operations or financial results.
Editas Medicine, Inc. director Bernadette Connaughton received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share, are scheduled to vest in full on June 17, 2027, and expire on June 16, 2036. Following this compensation award, she holds 51,700 derivative securities directly, with no open-market buy or sell reported.
Editas Medicine director Jessica Hopfield received a new stock option grant. On June 17, 2026, she was awarded options to acquire 51,700 shares of Editas Medicine common stock at an exercise price of $2.55 per share.
The option is scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this grant, she holds options covering 51,700 shares directly as reported in this filing.